引用本文:王 红,娄 奇,李为民.沙库巴曲缬沙坦在射血分数保留心力衰竭患者中的临床研究进展[J].中国临床新医学,2021,14(6):545-548.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 220次   下载 279 本文二维码信息
码上扫一扫!
分享到: 微信 更多
沙库巴曲缬沙坦在射血分数保留心力衰竭患者中的临床研究进展
王 红,娄 奇,李为民
150001 黑龙江,哈尔滨医科大学附属第一医院心血管内科五科
摘要:
[摘要] 目前我国心力衰竭(简称心衰)患病率高达1.3%,约1 370万例,心衰5年生存率不足50%,与恶性肿瘤相当,给我国心血管疾病防治工作带来沉重负担。沙库巴曲缬沙坦是全球首个血管紧张素受体脑啡肽酶抑制剂(ARNI)类药物,2017年在我国上市,2018年即被写入中国心衰指南,推荐用于射血分数降低心衰(HFrEF)患者。然而射血分数保留心衰(HFpEF)约占心衰人群一半,目前尚缺乏可以真正改善HFpEF患者预后的药物。这一局面被2021年2月16日美国食品药品监督管理局(FDA)批准的“沙库巴曲缬沙坦治疗慢性心衰的扩展适应证”所打破。该文就近年来沙库巴曲缬沙坦在心衰领域重大研究进展进行解读和总结,并着重分析其在HFpEF患者中的证据支持。
关键词:  沙库巴曲缬沙坦  射血分数保留心力衰竭  心力衰竭  心血管死亡风险  心衰住院风险
DOI:10.3969/j.issn.1674-3806.2021.06.04
分类号:R 541.6
基金项目:
Clinical research progress of sacubitril/valsartan in patients suffering from heart failure with preserved ejection fraction
WANG Hong, LOU Qi, LI Wei-min
The Fifth Department of Cardiovascular Medicine, the First Affiliated Hospital of Harbin Medical University, Heilongjiang 150001, China
Abstract:
[Abstract] At present, the prevalence rate of heart failure(HF) in China is as high as 1.3%, about 13.7 million cases, and the 5-year survival rate of HF is less than 50%, which is equivalent to that of malignant tumors, bringing a heavy burden to the prevention and treatment of cardiovascular diseases in China. Sacubitril/valsartan is the first angiotensin receptor neprilysin inhibitor(ARNI) drug in the world. In 2017, sacubitril/valsartan was marketed in China. In 2018, sacubitril/valsartan was included in the Chinese Heart Failure Guidelines and recommended for patients suffering from heart failure with reduced ejection fraction(HFrEF). However, heart failure with preserved ejection fraction(HFpEF) accounts for about half of the HF population, and there is still a lack of drugs that can truly improve the prognoses of HFpEF patients.This situation was broken by the “Expanded Indications for the Treatment of Chronic Heart Failure with Sacubitril/Valsartan” approved by the United States Food and Drug Administration(FDA) on February 16, 2021. This paper interprets and summarizes the major research progress of sacubitril/valsartan in the field of HF in recent years, and focuses on the analysis of its evidence support in patients with HFpEF.
Key words:  Sacubitril/valsartan  Heart failure with preserved ejection fraction(HFpEF)  Heart failure(HF)  Risk of cardiovascular death  Risk of hospitalization for heart failure